Therefore, it is very likely that low-dose ASA treatment significantly modifies the inflammatory tumor microenvironment by decreasing the MIB-1 labeling index in female elderly non-skull-base meningioma patients, leading to a reduced risk of symptomatic epilepsy. Here, MIB1 is linked to skull base meningioma.